| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 10/02/2022 | 18:31 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:ODT | Odonate Therapeutics Inc |
| 07/02/2022 | 15:01 | Edgar (US Regulatory) | Termination of Registration of a Class of Security Under Section 12(b) (15-12b) | NASDAQ:ODT | Odonate Therapeutics Inc |
| 31/01/2022 | 12:14 | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:ODT | Odonate Therapeutics Inc |
| 26/01/2022 | 15:01 | Edgar (US Regulatory) | Post-effective Amendment to an S-8 Filing (s-8 Pos) | NASDAQ:ODT | Odonate Therapeutics Inc |
| 26/01/2022 | 15:01 | Edgar (US Regulatory) | Post-effective Amendment to Registration Statement (pos Am) | NASDAQ:ODT | Odonate Therapeutics Inc |
| 25/01/2022 | 23:31 | Edgar (US Regulatory) | Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse) | NASDAQ:ODT | Odonate Therapeutics Inc |
| 07/01/2022 | 15:01 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ODT | Odonate Therapeutics Inc |
| 07/01/2022 | 15:00 | Business Wire | Odonate Announces Expected Delisting of Its Stock | NASDAQ:ODT | Odonate Therapeutics Inc |
| 11/12/2021 | 00:50 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ODT | Odonate Therapeutics Inc |
| 22/11/2021 | 17:09 | Edgar (US Regulatory) | Amended Statement of Beneficial Ownership (sc 13d/a) | NASDAQ:ODT | Odonate Therapeutics Inc |
| 17/11/2021 | 13:45 | Business Wire | Odonate Therapeutics Announces Planned Return of Capital to Stockholders through Share Repurchase Plan | NASDAQ:ODT | Odonate Therapeutics Inc |
| 10/11/2021 | 23:15 | Business Wire | Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021 | NASDAQ:ODT | Odonate Therapeutics Inc |
| 10/11/2021 | 23:02 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:ODT | Odonate Therapeutics Inc |
| 08/09/2021 | 13:00 | GlobeNewswire Inc. | SHAREHOLDER ALERT: Morris Kandinov Investigating ODT, AYTU, EAR, and CORT; Shareholders are Encouraged to Contact the Firm | NASDAQ:ODT | Odonate Therapeutics Inc |
| 27/07/2021 | 14:30 | Business Wire | Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021 | NASDAQ:ODT | Odonate Therapeutics Inc |
| 02/07/2021 | 22:07 | Edgar (US Regulatory) | Statement of Ownership (sc 13g) | NASDAQ:ODT | Odonate Therapeutics Inc |
| 01/06/2021 | 22:31 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NASDAQ:ODT | Odonate Therapeutics Inc |
| 14/05/2021 | 14:30 | Business Wire | Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021 | NASDAQ:ODT | Odonate Therapeutics Inc |
| 12/04/2021 | 14:02 | Edgar (US Regulatory) | Schedule 13g | NASDAQ:ODT | Odonate Therapeutics Inc |
| 22/03/2021 | 13:00 | Business Wire | Odonate Therapeutics Announces Discontinuation of Development of Tesetaxel | NASDAQ:ODT | Odonate Therapeutics Inc |
| 23/02/2021 | 14:30 | Business Wire | Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 | NASDAQ:ODT | Odonate Therapeutics Inc |
| 23/02/2021 | 14:11 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) | NASDAQ:ODT | Odonate Therapeutics Inc |
| 23/02/2021 | 13:32 | Edgar (US Regulatory) | Annual Report (10-k) | NASDAQ:ODT | Odonate Therapeutics Inc |
| 11/12/2020 | 16:05 | Business Wire | Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 S... | NASDAQ:ODT | Odonate Therapeutics Inc |
| 07/12/2020 | 14:30 | Business Wire | Odonate Therapeutics Initiates Cohort 3 of CONTESSA TRIO to Evaluate Tesetaxel Monotherapy in Patients with Metastatic Breast... | NASDAQ:ODT | Odonate Therapeutics Inc |
| 01/12/2020 | 14:30 | Business Wire | Odonate Therapeutics to Host Virtual Investor and Analyst Event on December 11, 2020 | NASDAQ:ODT | Odonate Therapeutics Inc |
| 27/11/2020 | 15:01 | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3) | NASDAQ:ODT | Odonate Therapeutics Inc |
| 28/10/2020 | 13:30 | Business Wire | Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2020 | NASDAQ:ODT | Odonate Therapeutics Inc |
| 05/10/2020 | 14:30 | Business Wire | Results of CONTESSA, a Phase 3 Study of Tesetaxel in the Treatment of Patients with Metastatic Breast Cancer, to Be Presented... | NASDAQ:ODT | Odonate Therapeutics Inc |
| 28/08/2020 | 01:45 | Business Wire | Odonate Therapeutics Announces Pricing of Public Offering of Shares of Common Stock | NASDAQ:ODT | Odonate Therapeutics Inc |